[PDF][PDF] Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis

J Li, M Guo, X Tian, X Wang, X Yang, P Wu, C Liu… - Med, 2021 - cell.com
Background The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global public health …

COVID-19: The emerging immunopathological determinants for recovery or death

T Ahmad, R Chaudhuri, MC Joshi… - Frontiers in …, 2020 - frontiersin.org
Hyperactivation of the host immune system during infection by SARS-CoV-2 is the leading
cause of death in COVID-19 patients. It is also evident that patients who develop …

[HTML][HTML] Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

J Yang, YA Zheng, X Gou, K Pu, Z Chen, Q Guo… - International journal of …, 2020 - Elsevier
Background An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan,
China; the epidemic is more widespread than initially estimated, with cases now confirmed …

The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID

J Li, Y Zhou, J Ma, Q Zhang, J Shao, S Liang… - … and Targeted Therapy, 2023 - nature.com
There have been hundreds of millions of cases of coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With …

COVID-19: in the eye of the cytokine storm

R De la Rica, M Borges, M Gonzalez-Freire - Frontiers in immunology, 2020 - frontiersin.org
The dysregulated release of cytokines has been identified as one of the key factors behind
poorer outcomes in COVID-19. This “cytokine storm” produces an excessive inflammatory …

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

IP Trougakos, K Stamatelopoulos, E Terpos… - Journal of Biomedical …, 2021 - Springer
Background Gaining further insights into SARS-CoV-2 routes of infection and the underlying
pathobiology of COVID-19 will support the design of rational treatments targeting the life …

Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study

E Ge, Y Li, S Wu, E Candido, X Wei - PLoS One, 2021 - journals.plos.org
Background The novel coronavirus disease 2019 (COVID-19) has infected 1.9% of the world
population by May 2, 2021. Since most previous studies that examined risk factors for …

Pathophysiology of COVID-19: mechanisms underlying disease severity and progression

MK Bohn, A Hall, L Sepiashvili, B Jung… - …, 2020 - journals.physiology.org
The global epidemiology of coronavirus disease 2019 (COVID-19) suggests a wide
spectrum of clinical severity, ranging from asymptomatic to fatal. Although the clinical and …

Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study

R Chang, TYT Chen, SI Wang, YM Hung… - …, 2023 - thelancet.com
Background There are a growing number of case reports of various autoimmune diseases
occurring after COVID-19, yet there is no large-scale population-based evidence to support …

COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies

R Raman, KJ Patel, K Ranjan - Biomolecules, 2021 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major …